All articles by MarketLine  

1. Sanofi restructure investment to focus on blooming business ventures

   Paris-based pharmaceutical company Sanofi sells $13bn stake in biotech Regeneron. The biotech company will repurchase $5bn of stock from Sanofi,…
   Read More…

   26 May
2. Covid-19 epidemic will reshape patient behaviour, accelerating digitalisation of healthcare system

   The projected timeline for adopting digital medical services is becoming significantly shorter due to the impacts of Covid-19. Prior to…
   Read More…

   23 Mar
3. Pharmaceuticals contrasts travel and tourism following China’s coronavirus outbreak

   Chinese drugmakers experience a 10% increase in share prices following a rising number of people infected by the coronavirus. Maximum…
   Read More…

   22 Jan
4. Psilocybin moves closer to becoming a licensed treatment for depression

   The main psychoactive component in magic mushrooms, psilocybin, has passed its first clinical safety trial.  The drug is now closer…
   Read More…

   19 Dec
5. Inclisiran drives Novartis to buy The Medicines Company

   Drug maker Novartis could become a leader in CVD therapeutics after purchasing The Medicine Company and its Atherosclerotic cardiovascular disease…
   Read More…

   3 Dec
6. Climate change means fresh opportunities for pharmaceutical companies

   According to an analysis of corporate disclosures conducted by the Carbon Disclosure Project (CDP), increasing numbers of world’s largest companies…
   Read More…

   21 Jun
7. The race to buy gene therapy developers is intensifying

   The recent acquisitions of Spark Therapeutics and Nightstar Rx signals the race to acquire gene therapy delivery platforms is well…
   Read More…

   14 Mar
8. Trump administration proposal may neuter America’s tapeworm PBMs

   The United States Department of Health and Human Services has proposed new limitations on pharmacy benefit manager (PBM) rebates. The…
   Read More…

   26 Feb
9. Why Sangamo’s shares tanked by 48%

   The collapse Sangamo Therapeutics’ shares, by 48%, after results of its Champions trial were released has raised questions about the…
   Read More…

   8 Feb
10. Can BMS make a success of its Celgene acquisition?

    Pharmaceutical company Bristol-Myers Squibb (BMS) has bought US biotech Celgene for $74bn as it seeks to leave its troubles behind….
    Read More…

    10 Jan